| |
Tuesday, February 7, 2023 | 11am ET / 8am PT This session will focus upon understanding your knowns and unknowns, best practices for mitigating risk, and addressing the specific drug supply challenges commonly associated with complex trial designs. Register now.
|
|
Today's Big NewsFeb 2, 2023 |
|
Thursday, Feb 16, 2023 | 2:00pm ET During this session, NetApp will explore how data is leveraged in Life Sciences to create a data fabric strategy that’s aligned to your business. This includes how to detailing each cycle of the data foundation for data governance and quality, data accessibility, data platforms, data as a service, data as a business, predictive intelligence, optimizing how solutions are managed across the data lifecycle, and more. Register now.
|
|
| By Andrea Park One quarter after announcing a plan to save around 300 million euros in its diagnostic testing division—namely, by laying off an undisclosed number of workers and exiting less lucrative regions—Siemens Healthineers still aims to stanch the department’s losses. |
|
|
|
By Fraiser Kansteiner Amid supply squeezes and mainstream hype for injectable incretin meds as an off-label resource for weight loss, Eli Lilly is attempting to run a tight ship with its marketing of Mounjaro. |
By Dave Muoio Days after the legal dispute over contract pharmacies shifted in pharma's favor, Bayer and EMD Serono became the 20th and 21st drugmakers with policies limiting discounted product sales to contract pharmacies. |
By Annalee Armstrong CEO David Ricks expressed a shrug over the FDA rejection of the accelerated review for Alzheimer’s med donanemab, while the company’s chief scientist batted back concerns that the FDA was worried about safety. |
|
Tuesday, Feb 28, 2023 | 11:00am ET The heavy lifting for the pharmaceutical industry to comply with the November 2023 DSCSA go-live date is still ongoing. One item now finalized is to ensure that the required data exchange through the supply chain is only done with trusted, authorized, and registered trading partners. Join us for this discussion to stay up-to-date on this important legislation and be prepared for compliance. Register now.
|
|
By Andrea Park BD's COVID-19 tests brought in a relatively measly $32 million for the first quarter of its fiscal year 2023, barely one-sixth of the $185 million it earned for the same three months the year prior. |
By Zoey Becker With three first-in-class launches, Bristol Myers Squibb enjoyed a productive year in 2022. One drug, Sotyku, has only been on the market for five months but is performing well so far, BMS says. |
By Max Bayer Bristol Myers Squibb has dumped nearly 10 early to mid-stage assets as part of a new year pipeline cleanout, including a phase 2 solid tumor candidate. The news comes just a day after the company ended a phase 2 trial testing its anti-TIGIT candidate. |
By Annie Burky The Federal Trade Commission invoked the Health Breach Notification Rule for the first time as an enforcement action against the online pharmacy GoodRx. According to the complaint, the company failed to notify customers and regulators of unauthorized disclosures of consumers’ personal health information. |
By Conor Hale “Excluding COVID-19 revenues” are the words of the day as Hologic posted coronavirus diagnostic and company-wide sales numbers for the first quarter of its fiscal year. |
By James Waldron Once neck and neck with Valneva to get the first chikungunya vaccine to market, it now looks like Merck & Co. has admitted defeat as its French rival reaches the finish line. |
By Eric Sagonowsky Even as mRNA specialist BioNTech plants its manufacturing flag on continents around the globe, the company is still advancing production capabilities at home. |
By Robert King CMS is proposing a 1.03% increase to Medicare Advantage and Part D plan payments for 2024 as well as several changes to the programs' risk adjustment model. |
By Conor Hale Sense acquired a CE Mark approval in Europe last year for its Veros test for COVID-19. |
Fierce podcastsDon't miss an episode |
| | This week on "The Top Line," we hear from Stacie Dusetzina, Ph.D., a professor at Vanderbilt University's Department of Health Policy, about what the IRA means for the pharma industry. We'll also discuss what we can expect from the biotech industry in 2023. |
|
|---|
|
|
|
The global demand for biologics is projected to increase considerably by 2030, but the challenges, risks, and costs are also growing. For pharma companies looking to bring a new biologic to market, meeting clinical trial milestones can be difficult. To access important insights, download this executive summary now.
|
|
| Whitepaper Discover the Power of Small with NanoplasmidTM – the next-generation plasmid for manufacturing today’s cell and gene therapies. Sponsored by: Aldevron |
| WhitepaperThis paper explores the cost drivers behind gene therapies and how they are likely to evolve in the coming years. Sponsored by: Blue Matter |
| WhitepaperExploring the biology of G Protein-Coupled Receptors (GPCRs) and outlining a novel approach for developing therapeutics against previously undruggable GPCRs Sponsored by: Orion Biotechnology |
| WhitepaperLearn more about critical success factors for your next launch based on the experience of 100+ pharma product launches. Sponsored by: Herspiegel Consulting |
| WhitepaperRCTs with digital twins require fewer control patients and shorten trial timelines for Alzheimer's disease. Sponsored by: Unlearn AI |
| Whitepaper What makes nucleotides suitable for current good manufacturing practices? Sponsored by: Thermo Fisher Scientific |
| On-Demand Webinar See how high-throughput DNA synthesis combined with antibody engineering expertise provides end-to-end antibody discovery solutions. Sponsored by: Twist Bioscience |
| Whitepaper Download this paper to learn considerations on how to move a biologic through clinical trials faster, advantages of Parallel Processing, and more. Sponsored by: Catalent |
| WhitepaperWhat are key considerations for intranasal delivery in the treatment of acute and chronic conditions? Sponsored By: Catalent |
| Case Study Learn more on an approach for process characterization for the production of a monoclonal antibody, which will improve the efficiency and effectiveness of the process by targeting the right design and number of experiments. Sponsored by: Catalent |
| WhitepaperLearn how Catalent’s extensive network across APAC can meet a wide range of clinical supply needs for sponsors conducting trials within the region. Sponsored by: Catalent |
| WhitepaperExplore Catalent’s newest clinical supply facility in Japan, including the comprehensive services & solutions it offers to help support trials both in-country & around the world. Sponsored by: Catalent |
| |
|
